MARCELO JUNQUEIRA ATANAZIO
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/31 - Laboratório de Genética e Hematologia Molecular, Hospital das Clínicas, Faculdade de Medicina
LIM/31 - Laboratório de Genética e Hematologia Molecular, Hospital das Clínicas, Faculdade de Medicina
7 resultados
Resultados de Busca
Agora exibindo 1 - 7 de 7
conferenceObject Treating multiple myeloma in a resource-limited setting: real-world outcomes(2022) MATINEZ, Gracia; SEGURO, Fernanda; JACOMASSI, Mayara; VISNADI, Helena; ATANAZIO, Marcelo; SZOR, Roberta; NEFFA, Pedro; PEREIRA, Thales; SILVA, Wellington; DORLHIAC, Pedro; VELASQUES, Rodrigo; BASSOLI, Lucas; ROCHA, VandersonconferenceObject High-dose chemotherapy with autologous stem cell transplant (HDCT) for patients (pts) with advanced germ-cell tumors (aGCT): Real-world evidence from a tertiary cancer center in Brazil.(2023) POLHO, Gabriel Berlingieri; CUNHA, Mateus Trinconi; XAVIER, Erick Menezes; SILVA, Jamile Almeida; HIDALGO FILHO, Cassio Murilo Trovo; CRUSOE, Nathalia de Souza Del Rey; ATANAZIO, Marcelo Junqueira; HORITA, Vivian; FREITAS, Guilherme Fialho de; MUNIZ, David Queiroz Borges; ROCHA, Vanderson Geraldo; MOTA, Jose MauricioconferenceObject Comparative Analysis of Conditioning Regimens in Patients Undergoing Autologous Hematopoietic STEM CELL Transplant for Lymphoma in a Single Brazilian Center(2019) SCHMIDT-FILHO, Jayr; RAYOL, Sergio; YAMAGUCHI, Marcela; ATANAZIO, Marcelo; MARIANO, Livia; ROSSETTI, Renata; ROCHA, Vanderson- Consolidative mediastinal radiotherapy for advanced‑stage classical Hodgkin lymphoma with bulky disease in patients who achieve complete response after chemotherapy in PET-CT era(2022) ATANAZIO, M. J.; SANTOS, F. M.; DURAN, A.; MAIA, A. C. A.; ALVES, L. B.; VELASQUES, R. D.; ROCHA, V.; BUCCHERI, V.Background: The role of consolidation mediastinal radiotherapy (RT) for mediastinal bulky disease in advanced-stage classical Hodgkin lymphoma (cHL) is controversial in the positron emission tomography/computed tomography (PET-CT) era. Materials and methods: We reviewed the medical charts of patients with advanced-stage (clinical stage IIX–IVX) cHL and mediastinal bulky that achieved a complete response after first line chemotherapy treatment between August 2010 and December 2020 and compared the results of those who received with those who did not receive consolidation mediastinal RT. Inclusion criteria required PET-CT imaging for staging and response assessment. Results: We included 115 patients; 91 received mediastinal RT and 24 did not. Patient’s characteristics were balanced between the two groups. The median age in patients that received and did not receive mediastinal RT was 28 years and 24.5 years, respectively. Median International Prognostic Score among patients that received and did not receive mediastinal RT was 2 and 2.5, respectively. Disease free survival (DFS) was statistically better in patients that received mediastinal RT (p = 0.013). Two-year DFS for patients that received and did not receive mediastinal RT was 95.2% [95% confidence interval (95% CI): 87.6–98.2%] and 76.4% (95% CI: 52.2–89.4%), respectively. Overall survival (OS) was not different between the two groups (p = 0.617). In multivariate analysis, not receiving mediastinal radiotherapy and only achieving partial response (vs. complete response) after 2 cycles of chemotherapy were factors predictive of lower DFS. Conclusion: DFS, but not OS, was superior in patients that received mediastinal RT. © 2022 Greater Poland Cancer Centre.
- Concerns about Prognostic Meaning of Quantitative PET Analysis in Classical Hodgkin Lymphoma(2022) SANTOS, Fernanda Maria Maria; MARIN, Jose Flavio Gomes; LIMA, Marcos Santos; SILVA, Wellington F.; VELASQUES, Rodrigo D.; MAIA, Ana Carolina Arrais; ATANAZIO, Marcelo Junqueira; ALVES, Lucas Bassolli de Oliveira; MOREIRA, Frederico Rafael; BUCHPIGUEL, Carlos Alberto; BUCCHERI, Valeria; ROCHA, Vanderson
- Rescue of chemorefractory classical Hodgkin lymphoma with nivolumab and autologous stem-cell transplantation: Real-life experience(2021) BUCCHERI, Valeria; FATOBENE, Giancarlo; SANTOS, Fernanda M.; VELASQUES, Rodrigo D.; BELLESSO, Marcelo; ATANAZIO, Marcelo J.; ROCHA, Vanderson
- Impact of baseline and interim quantitative PET parameters on outcomes of classical Hodgkin Lymphoma(2024) SANTOS, Fernanda Maria; MARIN, Jose Flavio Gomes; LIMA, Marcos Santos; SILVA-JUNIOR, Wellington Fernandes; ALVES, Lucas Bassolli O.; MOREIRA, Frederico R.; VELASQUES, Rodrigo Dolphini; ATANAZIO, Marcelo Junqueira; MAIA, Ana Carolina Arrais; BUCHPIGUEL, Carlos A.; BUCCHERI, Valeria; ROCHA, VandersonCurrently, analysis of interim PET (iPET) according to the Deauville score (DS) is the most important predictive factor in Hodgkin lymphoma (HL); however, there is room for improvement in its prognostic power. This study aimed to evaluate the prognostic value of quantitative PET analysis (maximum standard uptake value [SUVmax], total metabolic tumor volume [TMTV] and total lesion glicolysis [TLG]) at baseline (PET0) and iPET in a retrospective cohort of newly diagnosed classical HL. For positive iPET (+ iPET), the reduction of quantitative parameters in relation to PET0 (Delta SUVmax, Delta TMTV and Delta TLG) was calculated. Between 2011 and 2017, 234 patients treated with ABVD were analyzed. Median age was 30 years-old, 59% had advanced stage disease, 57% a bulky mass and 25% a + iPET (DS 4-5). At baseline, high TLG was associated with an increased cumulative incidence of failure (CIF) (p = 0.032) while neither SUVmax, TMTV or TLG were associated with overall survival (OS) or progression-free survival (PFS). In multivariate analysis, only iPET was associated with CIF (p < 0.001). Among Delta SUVmax, Delta TMTV and Delta TLG, only a Delta SUVmax >= 68.8 was significant for PFS (HR: 0.31, CI95%: 0.11-0.86, p = 0.024). A subset of patients with improved PFS amongst + iPET was identified by the quantitative (Delta SUVmax >= 68.8%) analysis. In this real-world Brazilian cohort, with prevalent high-risk patients, quantitative analysis of PET0 did not demonstrate to be prognostic, while a dynamic approach incorporating the Delta SUV(max )to + iPET succeeded in refining a subset with better prognosis. These findings warrant validation in larger series and indicate that not all patients with + iPET might need treatment intensification.